SCHEMBL5882016

SCHEMBL5882016

CCCCCS(=O)(=O)NC(=O)c1ccc2[nH]c(C)c(Cc3ccncc3Cl)c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.43
POLB P06746 1/20 0.39
PTGS2 P35354 1/20 0.38
MAPT P10636 3/20 0.37
MAPK3 P27361 1/20 0.37
MAPK1 P28482 1/20 0.37
MCL1 Q07820 2/20 0.37
TBXAS1 P24557 1/20 0.36
ROCK2 O75116 2/20 0.36
PTPN1 P18031 1/20 0.35
TP53 P04637 1/20 0.35
PTPN5 P54829 1/20 0.35
KLKB1 P03952 1/20 0.35
MAP4K1 Q92918 1/20 0.35
KDM4E B2RXH2 1/20 0.35
PSMD14 O00487 1/20 0.35
RECQL P46063 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5882152 0.88 MAPT (0.49) PPARGPOLBPTGS2MAPTMCL1
SCHEMBL5881578 0.87 PPARG (0.55) PPARGMAPTMCL1CNR1
SCHEMBL5881907 0.86 PPARG (0.54) PPARGMAPTMCL1PTPN1KDM4E
SCHEMBL5881789 0.86 PPARG (0.54) PPARGMAPTMCL1PTPN1KDM4E
SCHEMBL6320738 0.85 PPARG (0.46) PPARGPTGS2MAPTPTPN1TP53
SCHEMBL5882099 0.85 PPARG (0.46) PPARGPTGS2MAPTMCL1PTPN1
SCHEMBL5881695 0.84 PPARG (0.51) PPARGPTGS2MAPTMCL1KDM4E
SCHEMBL5881755 0.83 PTPN1 (0.48) PPARGPTGS2MAPTMCL1PTPN1
SCHEMBL6134732 0.83 MAPT (0.44) PPARGPOLBMAPTMCL1TP53
SCHEMBL6319585 0.83 PPARG (0.44) PPARGPTGS2MAPTPTPN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115647-B2 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. (US) 2006-10-03 US disclosed
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. 2002-10-03 US disclosed
US-6410584-B1 ANTICANCER AGENTS CELL PATHWAYS, INC. 2002-06-25 US disclosed
EP-1132087-A1 REMEDIES FOR POLYCYSTIC OVARY SYNDROME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives IDO1, IDO2, INMT PPARG 4239/4885POLB 3300/4885PTGS2 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.